Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting
June 05 2022 - 6:00AM
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage
pharmaceutical company with a Research & Development
(“R&D”) innovation engine that aims to discover, develop and
ultimately deliver impactful medicines to patients, today announced
presentation of the first preclinical data for LB101, PD-L1xCD47
LockBody, in a poster presentation at the 2022 American Society of
Clinical Oncology (ASCO) Annual Meeting which is taking place
virtually and in person from June 3-7, 2022 in Chicago, IL. The
poster presentation will be featured in the Developmental
Therapeutics – Immunotherapy session today, June 5, 2022, at 8-11
AM CT.
“We are excited to release the first preclinical data for LB101
from our LockBody platform which we believe has the potential to
fundamentally redefine immuno-oncology treatment for patients with
cancer. These results demonstrated that LB101 as a single-agent and
delivered systemically, led to meaningful and durable responses in
a difficult-to-treat mouse model with no apparent observed
toxicity,” said Saurabh Saha, MD, PhD, Chief Executive Officer of
Centessa.
The poster includes in vivo data in a MC38 hPD-L1+ syngeneic
mouse model, which demonstrated significantly improved efficacy
with durable responses for single-agent LB101 (26 of 32 tumors
eradicated across two doses) compared to isotype control IgG (0 of
16) and atezolizumab (4 of 32 across two doses). In rechallenge
experiments, none of the mice from groups with prior LB101-induced
regressions exhibited tumor growth compared to all naïve mice which
rapidly established tumors. At equimolar doses to atezolizumab,
LB101 exhibited no anemia, weight-loss or overt toxicity. The
poster also includes in vitro data, which demonstrated PD-L1
binding in the locked form and CD47 binding with strongly enhanced
antibody-dependent cellular phagocytosis (ADCP) in the unlocked
form.
“The innovative design of our LockBody molecules takes advantage
of human IgG-derived hinges to enable tunable, tumor-specific
activation of the conditional effector Fab in the tumor
micro-environment after selectively enriching in the tumor with the
constitutive Fab of our construct. We plan to advance this exciting
LockBody program into the clinic late this year and to continue
building this potential platform with multiple novel constructs,”
added Antoine Yver, MD, MSc, Chairman of Development at
Centessa.
Details of the poster presentation:
- Title: LB101, a
conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody
(mAb), combines tumor microenvironment (TME) targeted delivery
(PD-L1) and a single biological high potency effector (CD47).
- Poster session:
Developmental Therapeutics – Immunotherapy
- Date, time and
location: June 5, 2022, 8-11 AM Central Time, Chicago,
IL.
- Abstract and poster
numbers: Abstract 2562; poster 217
The poster is now live on the ASCO Annual Meeting website at
https://conferences.asco.org/am/attend.
About Centessa Pharmaceuticals
Centessa is a clinical-stage pharmaceutical company with an
R&D innovation engine that aims to discover, develop and
ultimately deliver impactful medicines to patients. Our programs
span discovery-stage to late-stage development and cover a range of
high-value indications in rare diseases and immuno-oncology. We are
led by a management team with extensive R&D experience,
providing direct guidance to our program teams to rapidly advance
our candidates from research through all stages of development. For
more information, visit www.centessa.com, which does not form part
of this release.
Forward Looking Statements
This press release contains forward-looking statements. These
statements may be identified by words such as “may,” “might,”
“will,” “could,” “would,” “should,” “expect,” “intend,” “plan,”
“objective,” “aim,” “aspire,” “anticipate,” “believe,” “estimate,”
“predict,” “potential,” “continue,” “ongoing,” “aim,” “seek,” and
variations of these words or similar expressions that are intended
to identify forward-looking statements. Any such statements in this
press release that are not statements of historical fact may be
deemed to be forward-looking statements, including statements
related to the Company’s ability to deliver impactful medicines to
patients; the ability of our key executives to drive execution of
the Company’s portfolio of programs including development of our
pre-clinical programs; our asset-centric business model and the
intended advantages and benefits thereof; research and clinical
development plans; the scope, progress, results and costs of
developing our product candidates or any other future product
candidates; the development and therapeutic potential of our
product candidates, including LB101; strategy; commencement and/or
completion dates for clinical trials; regulatory matters, including
the timing and likelihood of success of obtaining approvals to
initiate or continue clinical trials or market any products; market
size and opportunity for our product candidates as well as risks
associated with preliminary data, including the possibility of
unfavorable new preclinical or clinical trial data and further
analyses of existing preclinical or clinical trial data that may be
inconsistent with such preliminary data and our anticipated cash
runway. Any forward-looking statements in this press release are
based on our current expectations, estimates and projections only
as of the date of this release and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks related to the safety and
tolerability profile of our product candidates; our ability to
protect and maintain our intellectual property position; business,
regulatory, economic and competitive risks, uncertainties,
contingencies and assumptions about the Company; risks inherent in
developing products and technologies; future results from our
ongoing and planned clinical trials; our ability to obtain adequate
financing, including through our financing facility with Oberland,
to fund our planned clinical trials and other expenses; trends in
the industry; the legal and regulatory framework for the industry,
including the receipt and maintenance of clearances to conduct or
continue clinical testing; future expenditures risks related to our
asset-centric corporate model; the risk that any one or more of our
product candidates will not be successfully developed and/or
commercialized; the risk that the results of preclinical studies or
clinical studies will not be predictive of future results in
connection with future studies; geo-political risks such as the
Russia-Ukraine war and risks related to the ongoing COVID-19
pandemic including the effects of the Delta, Omicron and any other
variants. These and other risks concerning our programs and
operations are described in additional detail in our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2022 and our
other reports, which are on file with the U.S. Securities and
Exchange Commission. We explicitly disclaim any obligation to
update any forward-looking statements except to the extent required
by law.
Contact:
Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
investors@centessa.com
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Oct 2023 to Oct 2024